[Effect of ladasten on proliferative activity and apoptosis in peripheral blood T-lymphocytes ].

Vakhitova IuV, Sibiriak SV, Kurchatova NN, Seredenin SB

Eksperimental'naia i klinicheskaia farmakologiia1 Nov 2002

PMID12596534PepBankPUB-12596534

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. No result from this study comes from people.

01LabIn vitro (cells)Mechanism
In human T-lymphocytes, ladasten produced a comitogenic effect.
In plain wordsIn cells, ladasten enhanced multiplication of activated human T-lymphocytes.
Peptide
Bromantane
Outcome
IncreaseMitogenic stimulation
Study
humann: not reported in source
activated peripheral blood T-lymphocytes
Outcome group
Cell viability and death · Immune and inflammation
Studied dose
0.01-1 microM · 72 hoursAs given in this study (human).
Source sentences
Summary
In the concentration interval from 0.01 to 1 microM, ladasten produced a comitogenic effect.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of ladasten (0.1-10 microM) on the proliferative activity, apoptosis, and expression of the apoptosis protein regulators (bcl-2 and p53) was studied in 72-h cultures of T-lymphocytes of human peripheral blood activated by anti-CD3MCA.
Report a problemFND-1259653401
02LabIn vitro (cells)Mechanism
In activated human T-lymphocytes, ladasten did not change caspase 3 activity.
In plain wordsIn cells, ladasten did not change caspase 3 activity in activated human T-lymphocytes.
Peptide
Bromantane
Outcome
No significant changeCaspase activity
Study
humann: not reported in source
activated peripheral blood T-lymphocytes
Outcome group
Cell viability and death · Immune and inflammation
Studied dose
0.1-10 microM · 72 hoursAs given in this study (human).
Source sentences
Summary
The drug changed neither the activity of caspase 3 and the proportion of cells in the late apoptosis stage (Hoechst 33342 stain test), nor the bcl-2 expression, but increased the p53 expression in the activated cells.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of ladasten (0.1-10 microM) on the proliferative activity, apoptosis, and expression of the apoptosis protein regulators (bcl-2 and p53) was studied in 72-h cultures of T-lymphocytes of human peripheral blood activated by anti-CD3MCA.
Report a problemFND-1259653402
03LabIn vitro (cells)Mechanism
In activated human T-lymphocytes, ladasten did not change the proportion of cells in late apoptosis.
In plain wordsIn cells, ladasten did not change the proportion of activated human T-lymphocytes in late apoptosis.
Peptide
Bromantane
Outcome
No significant changeLate apoptosis
Study
humann: not reported in source
activated peripheral blood T-lymphocytes
Outcome group
Cell viability and death · Immune and inflammation
Studied dose
0.1-10 microM · 72 hoursAs given in this study (human).
Source sentences
Summary
The drug changed neither the activity of caspase 3 and the proportion of cells in the late apoptosis stage (Hoechst 33342 stain test), nor the bcl-2 expression, but increased the p53 expression in the activated cells.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of ladasten (0.1-10 microM) on the proliferative activity, apoptosis, and expression of the apoptosis protein regulators (bcl-2 and p53) was studied in 72-h cultures of T-lymphocytes of human peripheral blood activated by anti-CD3MCA.
Report a problemFND-1259653403
04LabIn vitro (cells)Mechanism
In activated human T-lymphocytes, ladasten did not change bcl-2 expression.
In plain wordsIn cells, ladasten did not change bcl-2 expression in activated human T-lymphocytes.
Peptide
Bromantane
Outcome
No significant changeBcl-2 expression
Study
humann: not reported in source
activated peripheral blood T-lymphocytes
Outcome group
Cell viability and death · Immune and inflammation
Studied dose
0.1-10 microM · 72 hoursAs given in this study (human).
Source sentences
Summary
The drug changed neither the activity of caspase 3 and the proportion of cells in the late apoptosis stage (Hoechst 33342 stain test), nor the bcl-2 expression, but increased the p53 expression in the activated cells.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of ladasten (0.1-10 microM) on the proliferative activity, apoptosis, and expression of the apoptosis protein regulators (bcl-2 and p53) was studied in 72-h cultures of T-lymphocytes of human peripheral blood activated by anti-CD3MCA.
Report a problemFND-1259653404
05LabIn vitro (cells)Mechanism
In activated human T-lymphocytes, ladasten increased p53 expression.
In plain wordsIn cells, ladasten increased p53 expression in activated human T-lymphocytes.
Peptide
Bromantane
Outcome
IncreaseP53 expression
Study
humann: not reported in source
activated peripheral blood T-lymphocytes
Outcome group
Cell viability and death · Immune and inflammation
Studied dose
0.1-10 microM · 72 hoursAs given in this study (human).
Source sentences
Summary
The drug changed neither the activity of caspase 3 and the proportion of cells in the late apoptosis stage (Hoechst 33342 stain test), nor the bcl-2 expression, but increased the p53 expression in the activated cells.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of ladasten (0.1-10 microM) on the proliferative activity, apoptosis, and expression of the apoptosis protein regulators (bcl-2 and p53) was studied in 72-h cultures of T-lymphocytes of human peripheral blood activated by anti-CD3MCA.
Report a problemFND-1259653405
06LabIn vitro (cells)Mechanism
In activated human lymphocytes, ladasten protected against apoptosis when added simultaneously with camptothecin.
In plain wordsIn cells, ladasten protected activated human lymphocytes from cell death when added at the same time as camptothecin.
Peptide
Bromantane
Outcome
DecreaseCamptothecin-induced apoptosis with simultaneous treatment
Study
humann: not reported in source
activated peripheral blood T-lymphocytes
Outcome group
Cell viability and death · Immune and inflammation
Studied dose
0.1-10 microM · 72 hoursAs given in this study (human).
Source sentences
Summary
Irrespective of the concentration, ladasten protected activated lymphocytes in the cell culture from apoptosis induced by the topoisomerase I inhibitor camptothecin or by hydrogen peroxide (provided that the drug was added to the culture simultaneously with the apoptosis inductor).
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of ladasten (0.1-10 microM) on the proliferative activity, apoptosis, and expression of the apoptosis protein regulators (bcl-2 and p53) was studied in 72-h cultures of T-lymphocytes of human peripheral blood activated by anti-CD3MCA.
Report a problemFND-1259653406
07LabIn vitro (cells)Mechanism
In activated human lymphocytes, ladasten protected against apoptosis when added simultaneously with hydrogen peroxide.
In plain wordsIn cells, ladasten protected activated human lymphocytes from cell death when added at the same time as hydrogen peroxide.
Peptide
Bromantane
Outcome
DecreaseHydrogen peroxide-induced apoptosis with simultaneous treatment
Study
humann: not reported in source
activated peripheral blood T-lymphocytes
Outcome group
Cell viability and death · Immune and inflammation
Studied dose
0.1-10 microM · 72 hoursAs given in this study (human).
Source sentences
Summary
Irrespective of the concentration, ladasten protected activated lymphocytes in the cell culture from apoptosis induced by the topoisomerase I inhibitor camptothecin or by hydrogen peroxide (provided that the drug was added to the culture simultaneously with the apoptosis inductor).
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of ladasten (0.1-10 microM) on the proliferative activity, apoptosis, and expression of the apoptosis protein regulators (bcl-2 and p53) was studied in 72-h cultures of T-lymphocytes of human peripheral blood activated by anti-CD3MCA.
Report a problemFND-1259653407
08LabIn vitro (cells)Mechanism
Human lymphocytes cultivated with ladasten acquired resistance to hydrogen peroxide-induced apoptosis.
In plain wordsIn cells, human lymphocytes cultivated with ladasten acquired resistance to hydrogen peroxide-induced cell death.
Peptide
Bromantane
Outcome
IncreaseResistance to hydrogen peroxide-induced apoptosis
Study
humann: not reported in source
activated peripheral blood T-lymphocytes
Outcome group
Cell viability and death · Immune and inflammation
Studied dose
0.1-10 microM · 72 hoursAs given in this study (human).
Source sentences
Summary
At the same time, lymphocytes cultivated in the presence of ladasten acquired resistance with respect to apoptosis induced by hydrogen peroxide, but not by camptothecin.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of ladasten (0.1-10 microM) on the proliferative activity, apoptosis, and expression of the apoptosis protein regulators (bcl-2 and p53) was studied in 72-h cultures of T-lymphocytes of human peripheral blood activated by anti-CD3MCA.
Report a problemFND-1259653408
09LabIn vitro (cells)Mechanism
Human lymphocytes cultivated with ladasten did not acquire resistance to camptothecin-induced apoptosis.
In plain wordsIn cells, human lymphocytes cultivated with ladasten did not acquire resistance to camptothecin-induced cell death.
Peptide
Bromantane
Outcome
No significant changeResistance to camptothecin-induced apoptosis
Study
humann: not reported in source
activated peripheral blood T-lymphocytes
Outcome group
Cell viability and death · Immune and inflammation
Studied dose
0.1-10 microM · 72 hoursAs given in this study (human).
Source sentences
Summary
At the same time, lymphocytes cultivated in the presence of ladasten acquired resistance with respect to apoptosis induced by hydrogen peroxide, but not by camptothecin.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of ladasten (0.1-10 microM) on the proliferative activity, apoptosis, and expression of the apoptosis protein regulators (bcl-2 and p53) was studied in 72-h cultures of T-lymphocytes of human peripheral blood activated by anti-CD3MCA.
Report a problemFND-1259653409

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
21 Oct 2026, 15:58 UTC
Study results updated
Version 1
21 Oct 2026, 12:50 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.